) connected to Most important ibrutinib resistance in MCL mobile traces. This observation was further more verified in 165 Major MCL samples wherever 15% in the tumors that did not reply to ibrutinib treatment had mutations in TRAF3 The authors declare which the analysis was done during the absence of https://joycek308afk1.bmswiki.com/user